BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 24452600)

  • 1. New oral anticoagulants in practice: pharmacological and practical considerations.
    Wang Y; Bajorek B
    Am J Cardiovasc Drugs; 2014 Jun; 14(3):175-89. PubMed ID: 24452600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel oral anticoagulants: a review of new agents.
    Wanat MA
    Postgrad Med; 2013 Jul; 125(4):103-14. PubMed ID: 23933899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):997-1001. PubMed ID: 25392439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP; Halperin JL
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative management of patients on new oral anticoagulants.
    Lai A; Davidson N; Galloway SW; Thachil J
    Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oral anticoagulants in non-valvular atrial fibrillation.
    Potpara TS; Lip GY
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):115-29. PubMed ID: 23953900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
    Contractor T; Levin V; Martinez MW; Marchlinski FE
    Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation: a GP primer on the new oral anticoagulants.
    Brieger D
    Aust Fam Physician; 2014 May; 43(5):254-9. PubMed ID: 24791763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY; Kim RB
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC; Easton JD; Hankey GJ; Hart RG
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
    Baker WL; Chamberlin KW
    Clin Pharmacol Ther; 2014 Jul; 96(1):17-9. PubMed ID: 24942397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
    Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
    Amin A; Stokes M; Makenbaeva D; Wiederkehr D; Wu N; Lawrence JH
    J Med Econ; 2014 Nov; 17(11):771-81. PubMed ID: 25133458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of the new oral anticoagulants: opportunities and challenges.
    Yeh CH; Hogg K; Weitz JI
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.